These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9371372)

  • 1. In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.
    Mercier RC; Penzak SR; Rybak MJ
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2573-5. PubMed ID: 9371372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
    Itokazu GS; Nathan C; Hariharan R; Kostman JR; Kabins SA; Weinstein RA
    Chemotherapy; 1996; 42(4):235-9. PubMed ID: 8804789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.
    Zelenitsky SA; Booker B; Laing N; Karlowsky JA; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 1999 Mar; 43(3):592-7. PubMed ID: 10049272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
    Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
    Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.
    Caron F; Gold HS; Wennersten CB; Farris MG; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2749-53. PubMed ID: 9420051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
    Hill RL; Smith CT; Seyed-Akhavani M; Casewell MW
    J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
    Zelenitsky SA; Karlowsky JA; Zhanel GG; Hoban DJ; Nicas T
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1407-8. PubMed ID: 9174212
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Houlihan HH; Rybak MJ
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1307-12. PubMed ID: 9174189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of clinafloxacin against multidrug-resistant Enterococcus faecium.
    Burney S; Landman D; Quale JM
    Antimicrob Agents Chemother; 1994 Jul; 38(7):1668-70. PubMed ID: 7979306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Stumpo C; Rybak MJ
    J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.
    Eliopoulos GM; Wennersten CB; Gold HS; Schülin T; Souli M; Farris MG; Cerwinka S; Nadler HL; Dowzicky M; Talbot GH; Moellering RC
    Antimicrob Agents Chemother; 1998 May; 42(5):1088-92. PubMed ID: 9593132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
    Aeschlimann JR; Zervos MJ; Rybak MJ
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2710-7. PubMed ID: 9756782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium.
    Herrera-Insúa I; Jacques-Palaz K; Murray BE; Rakita RM
    Antimicrob Agents Chemother; 1996 Apr; 40(4):886-90. PubMed ID: 8849245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.
    Matsumura SO; Louie L; Louie M; Simor AE
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2776-9. PubMed ID: 10543762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
    Baltch AL; Smith RP; Ritz WJ; Bopp LH
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ; Cappelletty DM; Moldovan T; Aeschlimann JR; Kaatz GW
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
    Lorian V; Fernandes F
    Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
    Fraise AP; Andrews J; Wise R
    J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.